Genmab A/SGMABNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+331.2%
5Y CAGR+96.7%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+331.2%/yr
vs +8.9%/yr prior
5Y CAGR
+96.7%/yr
Recent acceleration
Acceleration
+322.3pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
29.4x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 836.23% |
| Q3 2025 | -84.52% |
| Q2 2025 | 542.53% |
| Q1 2025 | -86.52% |
| Q4 2024 | 16.69% |
| Q3 2024 | 532.41% |
| Q2 2024 | 7.76% |
| Q1 2024 | -82.80% |
| Q4 2023 | -6.70% |
| Q3 2023 | 12.68% |
| Q2 2023 | 6.43% |
| Q1 2023 | 6.09% |
| Q4 2022 | 10.43% |
| Q3 2022 | 15.91% |
| Q2 2022 | 11.19% |
| Q1 2022 | -11.17% |
| Q4 2021 | 16.52% |
| Q3 2021 | 20.96% |
| Q2 2021 | 8.61% |
| Q1 2021 | -8.42% |
| Q4 2020 | 28.43% |
| Q3 2020 | -6.97% |
| Q2 2020 | 8.39% |
| Q1 2020 | 6.93% |
| Q4 2019 | 10.00% |
| Q3 2019 | 7.90% |
| Q2 2019 | 3.17% |
| Q1 2019 | 19.63% |
| Q4 2018 | 32.99% |
| Q3 2018 | 7.64% |
| Q2 2018 | 2.03% |
| Q1 2018 | 13.71% |
| Q4 2017 | 20.68% |
| Q3 2017 | 13.00% |
| Q2 2017 | 18.52% |
| Q1 2017 | -13.08% |
| Q4 2016 | 29.92% |
| Q3 2016 | -19.68% |
| Q2 2016 | 47.51% |
| Q1 2016 | -28.11% |